预防性两周格卡瑞韦/哌仑他韦用于HCV阳性供肾移植
本研究为前瞻性单中心单臂开放标签预试验,20例HCV阴性受者接受HCV阳性 deceased-donor 肾移植,术后给予14天格卡瑞韦/哌仑他韦(GLE/PIB)300/120 mg预防性治疗,首剂术前。结果显示35%受者未出现可检测病毒血症,仅1例POD13低病毒血症延长至8周,全部受者获得SVR12,1年无复发。
要点
- 14天预防性GLE/PIB方案安全有效,可使多数受者避免供者来源HCV感染。
- 35%受者未出现可检测HCV病毒血症,仅1例需延长至8周疗程。
- 所有受者均获得SVR12,1年随访无复发。
核心结论
- 14天预防性GLE/PIB方案对HCV阳性供肾移植安全有效,可预防HCV传播或显著降低病毒载量并在2周内快速清除。
研究设计与样本
- 前瞻性、单中心、单臂、开放标签预试验,纳入20例HCV阴性成人受者接受HCV NAT阳性 deceased-donor 肾移植。
- 受者接受14天GLE/PIB 300/120 mg,首剂术前,术后POD1、3、7、13监测HCV RNA,POD13检测不到则停药,可检测到则延长至8周。
主要发现
- 20例中7例(35%)从未出现可检测HCV病毒血症。
- 仅1例POD13可检测但不可定量,完成8周疗程。
- 所有受者获得SVR12,1年随访无复发。
- HCV RNA转阴平均时间10.5(±4.7)天,平均峰值病毒载量371(±715)copies/mL。
- 6个月和1年患者及移植物生存率分别为100%和95%。
临床怎么用
- HCV阳性供肾移植可考虑14天预防性GLE/PIB方案,首剂术前开始。
- 术后需在POD1、3、7、13监测HCV RNA,POD13可检测者延长疗程至8周。
局限性
- 单中心、单臂、开放标签、样本量小(20例),缺乏对照组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND HYPOTHESIS: Hepatitis C virus (HCV) positive-to-negative kidney transplants require direct-acting antiviral therapy, but the optimal timing and duration remain unclear. We hypothesized that a 14-day prophylactic course of glecaprevir/pibrentasvir 300/120 mg (GLE/PIB) would be safe and effective at treating donor-derived HCV viremia. METHODS: This was a prospective, single-center, single-arm, open-label pilot study. Twenty adult HCV-negative recipients of HCV nucleic acid amplification test positive deceased-donor kidneys (HCV positive-to-negative) received a 14-day course of GLE/PIB, with the first dose pretransplant. HCV RNA viral load (VL) was monitored on postoperative days (POD) 1, 3, 7, and 13. If VL was undetectable on POD 13, GLE/PIB was stopped, and if detectable, GLE/PIB was continued to complete an 8-week course. Surveillance monitoring continued after treatment to ensure sustained viral response (SVR). The primary outcome was efficacy of 14-day prophylactic GLE/PIB. Secondary outcomes included patient and allograft survival, the incidence, timing, and clearance of HCV viremia, and safety events. RESULTS: Seven out of 20 subjects (35%) never developed detectable HCV viremia. Only one subject had a detectable, but nonquantifiable, VL on POD 13 and completed an 8-week course. All subjects achieved SVR 12 weeks post-treatment with no relapses through 1-year follow-up. Mean time to undetectable HCV RNA VL was 10.5 (±4.7) days and mean peak VL was 371 (±715) copies/mL. Six-month and 1-year patient and allograft survival were 100% and 95%. CONCLUSION: A 14-day course of prophylactic GLE/PIB is safe and effective for HCV positive-to-negative kidney transplants and may prevent HCV transmission or significantly reduce the VL for those with detectable transmission, allowing rapid clearance within 2 weeks.
引用
- Dieter RA, Mattoo A, Hotchkis P, et al. Prophylactic 2-week glecaprevir/pibrentasvir in hepatitis C positive-to-negative kidney transplantation. Nephrol Dial Transplant. 2025. PMID: 39568065. doi:10.1093/ndt/gfae271
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。